Solventum (NYSE:SOLV - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $1.31 per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.
Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.05 billion. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Solventum Price Performance
SOLV traded down $1.35 during trading on Friday, hitting $73.43. 859,465 shares of the company traded hands, compared to its average volume of 970,471. Solventum has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock's 50-day simple moving average is $70.36 and its two-hundred day simple moving average is $67.80.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. Morgan Stanley upped their price objective on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. Finally, Piper Sandler raised their target price on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $68.29.
Read Our Latest Analysis on SOLV
About Solventum
(
Get Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Further Reading
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
